title: NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
abstract: Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland. Electronic address: ksenia.sevastianova@helsinki.fi.
authors.forename: Ksenia
authors.initials: K
authors.lastname: Sevastianova
authors.affiliation: National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Dean
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
authors.forename: Ciaran
authors.initials: C
authors.lastname: Bannan
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
authors.forename: Miriam
authors.initials: M
authors.lastname: Coghlan
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
authors.forename: Gillian
authors.initials: G
authors.lastname: Farrell
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
authors.forename: Catherine
authors.initials: C
authors.lastname: Murray
authors.affiliation: National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
authors.forename: Cillian F
authors.initials: CF
authors.lastname: De Gascun
authors.affiliation: Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, Ireland.
authors.forename: Colm
authors.initials: C
authors.lastname: Bergin
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005449:Fluorenes / Q000627:therapeutic use*; D005838:Genotype; D015658:HIV Infections / Q000150:complications; D015497:HIV-1 / Q000302:isolation & purification; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D012254:Ribavirin / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000627:therapeutic use*; D017211:Treatment Failure; D017361:Viral Nonstructural Proteins / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; D012254:Ribavirin; D000069474:Sofosbuvir; D017361:Viral Nonstructural Proteins; C586541:ledipasvir; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase
keywords: Direct-acting antivirals; HCV genotype 1a; HIV; Ledipasvir; Resistance; Sofosbuvir